Pathophysiology of depression: Do we have any solid evidence of interest to clinicians?;Patofizjologia depresji: Czy mamy jakieś solidne dowody naukowe przydatne klinicystom?

Postepy Psychiatrii i Neurologii

Volumn 20, Issue 1, 2011, Pages 5-13

  Hasler, Gregor ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Depression; Dopamine; GABA; Genetics; Glutamate; Neuroimaging; Norepinephrine; Pathophysiology; Serotonin; Stress

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; DOPAMINE; GLUTAMIC ACID; NEUROTROPHIC FACTOR; NORADRENALIN; SEROTONIN; STRESS HORMONE;

CIRCADIAN RHYTHM; CLINICAL PRACTICE; HUMAN; MAJOR DEPRESSION; MENTAL STRESS; PATHOPHYSIOLOGY; REVIEW;

EID: 84861870707     PISSN: 12302813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095-105. (Pubitemid 37432885)
2. Angst F, Stassen HH, Clayton PJ et al. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68:167-81. (Pubitemid 34628324)
3. Lopez AD, Mathers CD, Ezzati M et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367: 1747-57. (Pubitemid 43767064)
4. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000; 157:1552-62.
5. Kendler KS, Gardner CO, Prescott CA. Toward a comprehensive developmental model for major depression in men. Am J Psychiatry 2006;163:115-24. (Pubitemid 43050112)
6. Kendler KS, Gardner CO, Prescott CA. Toward a comprehensive developmental model for major depression in women. Am J Psychiatry 2002; 159:1133-45. (Pubitemid 34743253)
7. Elkin I, Shea MT, Watkins JT et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry 1989;46:971-82. (Pubitemid 19278225)
8. Leichsenring F, Rabung S, Leibing E. The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders: a meta-analysis. Arch Gen Psychiatry 2004; 61:1208-16. (Pubitemid 39602837)
9. Thase ME, Rush AJ, Manber R et al. Differ- ential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. J Clin Psychiatry 2002;63:493-500. (Pubitemid 34680357)
10. Kendler KS, Thornton 10. LM, Prescott CA. Gender differences in the rates of exposure to stressful life events and sensitivity to their depressogenic effects. Am J Psychiatry 2001;158:587-93. (Pubitemid 32289821)
11. Donnelly P. Progress and challenges in genome- wide association studies in humans. Nature 2008;456:728-31.
12. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-78.
13. Caspi A, Sugden K, Moffitt TE et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386-9. (Pubitemid 36877077)
14. Risch N, Herrell R, Lehner T et al. Interaction between the serotonin transporter gene (5-HTT LPR), stressful life events, and risk of depression: a meta-analysis. JAMA 2009;301:2462-71.
15. Hasler G, Drevets WC, Gould TD et al. Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry 2006;60:93-105. (Pubitemid 44026591)
16. Hasler G, Drevets WC, Manji HK et al. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004;29: 1765-81. (Pubitemid 39336788)
17. Young EA. Sex differences and the HPA axis: implications for psychiatric disease. J Gend Specif Med 1998;1:21-7.
18. Stroud LR, Salovey P, Epel ES. Sex differences in stress responses: social rejection versus achievement stress. Biol Psychiatry 2002;52:318-27. (Pubitemid 35245971)
19. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008;358:55-68.
20. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008; 31:464-8.
21. Heim C, Newport DJ, Mletzko T et al. The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology 2008;33:693-710.
22. Gold PW, Chrousos GP. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proceedings of the Association of American Physicians 1999;111:22-34. (Pubitemid 29047107)
23. Schule C. Neuroendocrinological mechanisms of actions of antidepressant drugs. J Neuroendocrinol 2007;19:213-26. (Pubitemid 46210949)
24. Mizoguchi K, Ishige A, Aburada M et al. Chronic stress attenuates glucocorticoid negative feedback: involvement of the prefrontal cortex and hippocampus. Neuroscience 2003;119:887-97. (Pubitemid 36694813)
25. Modell S, Yassouridis A, Huber J et al. Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology 1997;65:216-22. (Pubitemid 27107613)
26. Young EA, Lopez JF, Murphy-Weinberg V et al. Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry 2003;60:24-8. (Pubitemid 36070861)
27. McGowan PO, Sasaki A, D'Alessio AC et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nature Neurosci 2009;12:342-8.
28. Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 1994;28:341-56. (Pubitemid 24370022)
29. Bhagwagar Z, Hafizi S, Cowen PJ. Increased salivary cortisol after waking in depression. Psychopharmacology 2005;182:54-7. (Pubitemid 41400861)
30. Schatzberg AF, Lindley S. Glucocorticoid antagonists in neuropsychiatric [corrected] disorders. Eur J Pharmacol 2008;583:358-64.
31. Nemeroff CB, Widerlov E, Bissette G et al. Elevated concentrations of CSF corticotropin- releasing factor-like immunoreactivity in depressed patients. Science 1984;226:1342-4. (Pubitemid 15215592)
32. Raadsheer FC, Hoogendijk WJ, Stam FC et al. Increased numbers of corticotropinreleasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994;60:436-44. (Pubitemid 24284827)
33. Nemeroff CB, Owens MJ, Bissette G et al. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 1988;45:577-9.
34. Nemeroff CB. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol Psychiatry 1996;1:336-42. (Pubitemid 126441318)
35. Holsboer F, Ising M. Central CRH system in depression and anxiety - evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 2008;583:350-7.
36. Dantzer R, O'Connor JC, Freund GG et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Rev Neurosci 2008;9:46-56. (Pubitemid 350295688)
37. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004;82:175-90. (Pubitemid 39370819)
38. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008;455: 894-902.
39. Mendlewicz J, Kriwin P, Oswald P et al. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol 2006;21: 227-31. (Pubitemid 43740300)
40. Nemeroff CB, Heim CM, Thase ME et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA 2003;100:14293-6. (Pubitemid 37499230)
41. Neumeister A, Konstantinidis A, Stastny J et al. Association between serotonin transporter gene promoter polymorphism (5HTT LPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Arch Gen Psychiatry 2002;59:613-20. (Pubitemid 34747241)
42. Neumeister A, Nugent AC, Waldeck T et al. Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry 2004;61:765-73. (Pubitemid 39031116)
43. Drevets WC, Frank E, Price JC et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 1999;46:1375-87.
44. Neumeister A, Bain E, Nugent AC et al. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 2004;24: 589-91. (Pubitemid 38166482)
45. Hasler G, Bonwetsch R, Giovacchini G et al. 5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 2007; 62:1258-64. (Pubitemid 350060892)
46. Meyer JH, Ginovart N, Boovariwala A et al. Elevated monoamine oxidase A levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 2006;63:1209-16. (Pubitemid 44708079)
47. Zhang X, Gainetdinov RR, Beaulieu JM et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 2005;45:11-6. (Pubitemid 40075345)
48. Charney DS, Manji HK. Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE 2004;2004:re5.
49. Pandey GN, Dwivedi Y. Noradrenergic function in suicide. Arch Suicide Res 2007; 11:235-46.
50. Nutt DJ. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 2006;67 (Suppl. 6): 3-8. (Pubitemid 44078106)
51. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161:564-6. (Pubitemid 38326114)
52. Lambert G, Johansson M, Agren H et al. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry 2000;57:787-93. (Pubitemid 30650115)
53. Meyer JH, Kruger S, Wilson AA et al. Lower dopamine transporter binding potential in striatum during depression. Neuroreport 2001;12:4121-5. (Pubitemid 33152464)
54. Santamaria J, Tolosa E, Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986;36:1130-3. (Pubitemid 16038602)
55. Hasler G, Fromm S, Carlson PJ et al. Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry 2008;65:521-31. (Pubitemid 351645048)
56. Hasler G, Luckenbaugh DA, Snow J et al. Reward processing after catecholamine depletion in unmedicated, remitted subjects with major depressive disorder. Biol Psychiatry 2009;66:201-5.
57. Murphy FC, Michael A, Robbins TW et al. Neuropsychological impairment in patients with major depressive disorder: the effects of feedback on task performance. Psychol Med 2003;33:455-67. (Pubitemid 36442788)
58. Mann JJ. The medical management of depression. N Engl J Med 2005;353:1819-34.
59. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005;66:85-93.
60. Simpson D. Phrenology and the neurosciences: contributions of F. J. Gall and J. G. Spurzheim. ANZ J Surg 2005;75:475-82. (Pubitemid 40903095)
61. Fitzgerald PB, Laird AR, Maller J et al. A meta-analytic study of changes in brain activation in depression. Hum Brain Mapp 2008;29:683-95. (Pubitemid 351794123)
62. Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ et al. Brain volume abnormalities in major depressive disorder: a metaanalysis of magnetic resonance imaging studies. Hum Brain Mapp 2009;30:3719-35.
63. Rajkowska G, Miguel-Hidalgo JJ, Wei J et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999;45:1085-98. (Pubitemid 29236550)
64. Hercher C, Turecki G, Mechawar N. Through the looking glass: examining neuroanatomical evidence for cellular alterations in major depression. J Psychiatr Res 2009;43:947-61.
65. Price JL, Drevets WC. Neurocircuitry of mood disorders. Neuropsychopharmacology 2009;35:192-216.
66. Damasio AR, Tranel D, Damasio H. Individuals with sociopathic behavior caused by frontal damage fail to respond autonomically to social stimuli. Behav Brain Res 1990;41:81-94.
67. Sullivan RM, Gratton A. Lateralized effects of medial prefrontal cortex lesions on neuroendocrine and autonomic stress responses in rats. J Neurosci 1999;19:2834-40. (Pubitemid 29162429)
68. Mayberg HS, Lozano AM, Voon V et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005;45:651-60. (Pubitemid 40320700)
69. MacQueen GM. Magnetic resonance imaging and prediction of outcome in patients with major depressive disorder. J Psychiatry Neurosci 2009;34:343-9.
70. Kessing LV, Hansen MG, Andersen PK et al. The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders - a life-long perspective. Acta Psychiatr Scand 2004;109:339-44. (Pubitemid 38491280)
71. Sheline YI, Gado MH, Kraemer HC Untreated depression and hippocampal volume loss. Am J Psychiatry 2003;160:1516-8. (Pubitemid 41070930)
72. Hasler G, Fromm S, Alvarez RP et al. Cerebral blood flow in immediate and sustained anxiety. J Neurosci 2007;27:6313-9. (Pubitemid 46890032)
73. Frodl TS, Koutsouleris N, Bottlender R et al. Depression-related variation in brain morphology over 3 years: effects of stress? Arch Gen Psychiatry 2008;65:1156-65.
74. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nature Neurosci 2007;10:1089-93. (Pubitemid 47339961)
75. Hasler G, van der Veen JW, Tumonis T et al. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007;64:193-200. (Pubitemid 46220776)
76. Hasler G, van der Veen JW, Grillon C et al. Effect of acute psychological stress on prefrontal gamma-aminobutyric acid concentration determined by proton magnetic resonance spectroscopy. Am J Psychiatry (in press).
77. Rajkowska G, O'Dwyer G, Teleki Z et al. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology 2007;32:471-82. (Pubitemid 46106953)
78. Eser D, Schule C, Baghai TC et al. Neuroactive steroids in depression and anxiety disorders: clinical studies. Neuroendocrinology 2006;84:244-54. (Pubitemid 46391715)
79. Birkenhager TK, Moleman P, Nolen WA. Benzodiazepines for depression? A review of the literature. Int Clin Psychopharmacol 1995;10:181-95.
80. Hasler G, Neumeister A, van der Veen JW et al. Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy. Biol Psychiatry 2005;58:969-73. (Pubitemid 41790707)
81. Zarate CA, Jr., Singh JB, Carlson PJ et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63:856-64. (Pubitemid 44188478)
82. Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets 2005;9:153-68. (Pubitemid 40331202)
83. Feyissa AM, Chandran A, Stockmeier CA et al. Reduced levels of NR2A and NR2B subunits of NM DA receptor and PSD-95 in the pre-frontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:70-5.
84. Deschwanden A, Hasler G. Metabotropic glutamate receptor 5: role in depression? Presented at the 22nd European College of Neuropsychopharmacology Meeting, Istanbul, May 2009.
85. Bunney WE, Bunney BG. Molecular clock genes in man and lower animals: possible implications for circadian abnormalities in depression. Neuropsychopharmacology 2000;22:335-45. (Pubitemid 30105762)
86. Boivin DB, Czeisler CA, Dijk DJ et al. Complex interaction of the sleep-wake cycle and circadian phase modulates mood in healthy subjects. Arch Gen Psychiatry 1997;54:145-52. (Pubitemid 27074302)
87. Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum Psychopharmacol 2008;23:571-85.
88. Duncan WC, Jr. Circadian rhythms and the pharmacology of affective illness. Pharmacol Ther 1996;71:253-312.